Pulmonx
Pulmonx develops and sells minimally invasive medical devices for severe COPD/emphysema, led by the FDA-approved Zephyr Endobronchial Valve and supported by the Chartis Pulmonary Assessment System and StratX/LungTraX cloud diagnostic platforms, serving pulmonologists and hospitals across 25+ countries.
- Company typePublic
- Founded1995
- HeadquartersRedwood City, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pulmonx does
Pulmonx Corporation is a commercial-stage medical technology company that develops and sells minimally invasive devices and diagnostic platforms for the treatment of severe COPD and emphysema. The company's flagship product is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically that allows trapped air to escape damaged lung regions while preventing new air from entering. The Zephyr Valve received FDA approval in 2018 and is sold as an alternative to invasive lung volume reduction surgery. The company is headquartered in Redwood City, California, and was founded in 1995 (with some sources citing 1998); it trades on NASDAQ under ticker LUNG.
Pulmonx sells a procedural ecosystem rather than a single device. The Zephyr Valve is paired with the Chartis Pulmonary Assessment System (a console plus single-use Precision XL catheter that measures collateral ventilation to confirm patient eligibility) and the cloud-based StratX and LungTraX CT analysis platforms, which provide lung assessment reports used by treating physicians for candidate selection. Procedure economics are evidenced by 18% FEV1 improvement, 39-meter six-minute walk distance improvement, and 7.1-point SGRQ quality-of-life gains over controls, supported by four randomized controlled trials (LIBERATE, TRANSFORM, IMPACT, STELVIO).
The company monetizes primarily through hardware sales of Zephyr Valve implants and Chartis capital equipment and catheters to hospitals and treatment centers, with a smaller recurring subscription/analytics revenue stream from StratX and LungTraX. Go-to-market is a direct enterprise field sales motion targeting pulmonologists, interventional bronchoscopists, and hospitals, supported by a trained treatment-center network in 25+ countries, regional offices in Neuchâtel, Munich, and London, and reimbursement support (including NHS access in the UK via NICE). As of FY2025, revenue was $90.5 million with Q3 2025 gross margin of 75%, though the company remains EBITDA-negative.
Pulmonx firmographics
Firmographics- Name
- Pulmonx
- Legal name
- Pulmonx Corporation
- Website
- https://pulmonx.com
- Company type
- Public
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Pulmonx develops and sells minimally invasive medical devices for severe COPD/emphysema, led by the FDA-approved Zephyr Endobronchial Valve and supported by the Chartis Pulmonary Assessment System and StratX/LungTraX cloud diagnostic platforms, serving pulmonologists and hospitals across 25+ countries.
- Ownership category
- akta.pro rank
Pulmonx industry classification
Industry- Product category
- Interventional Pulmonology Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bronchoscopy & Interventional Pulmonology (HLAKANAJ)
- akta.pro secondary industry
- COPD & Chronic Bronchitis Management (HLAKANAE)
Keywords
Where Pulmonx is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Pulmonx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations
Revenue model
- Zephyr Valve Sales: Sale of Zephyr Endobronchial Valve implants to hospitals and treatment centers for bronchoscopic lung volume reduction procedures. Revenue recognized per procedure/implant.
- Chartis System Sales: Sale of Chartis Pulmonary Assessment System capital equipment (console) and single-use catheters used during patient assessment for Zephyr Valve eligibility.
- Diagnostic Platform Services: Revenue from StratX and LungTraX cloud-based analysis platforms used for patient selection and treatment planning.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Zephyr Valve treatment available on NHS and privately |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
Pulmonx product offering
Product offeringCore offering
Pulmonx develops and commercializes minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. Its core offering is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically to reduce hyperinflation in damaged lung regions without surgery. The offering is supported by the Chartis Pulmonary Assessment System, the StratX and LungTraX cloud-based CT analysis platforms, and AeriSeal lung sealant, sold to hospitals and specialized treatment centers worldwide.
Product overview
Pulmonx offers a portfolio of minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. The core product is the Zephyr Endobronchial Valve, an implantable bronchial valve that achieves lung volume reduction without surgery. This is supported by the Chartis Pulmonary Assessment System (comprising the Chartis Precision XL Catheter and Chartis Console) for measuring collateral ventilation, and the cloud-based StratX CT analysis platform for patient evaluation. Additional platforms include LungTraX for lung analysis. The Zephyr Valve is FDA-approved and CE-marked (Class IIb, CE 2797), and the products are used in over 25 countries as standard care for severe emphysema.
Differentiator
Problem solved
Functional benefit
Brands
- Zephyr Valve: Minimally invasive bronchoscopic treatment for patients with severe COPD/emphysema - the company's primary product
- Chartis System
- StratX
- AeriSeal
Products and services
- Zephyr Endobronchial Valve Minimally invasive implantable bronchoscopic one-way valve made from nitinol and silicone for the treatment of severe COPD/emphysema hyperinflation. Designed to reduce trapped air in damaged lung regions without surgery. Used by interventional pulmonologists at hospitals and treatment centers.
- Chartis Pulmonary Assessment System Bronchoscopic catheter and console system that measures pressure and flow to calculate resistance to airflow and quantify collateral ventilation in isolated lung compartments. Used by interventional pulmonologists to determine patient eligibility for Zephyr Valve treatment.
- Chartis Precision XL Catheter Single-use catheter component of the Chartis Pulmonary Assessment System, used through the bronchoscope working channel to measure pressure and flow during pulmonary assessment.
- StratX Lung Analysis Platform Cloud-based CT analysis platform that processes imaging data to generate detailed lung assessment reports for patient evaluation and treatment planning for Zephyr Valve procedures. Identifies candidates based on emphysema heterogeneity and lobar analysis.
- LungTraX Platform Cloud-based platform for lung analysis and patient assessment used in conjunction with other diagnostic tools for emphysema patient evaluation and treatment decisions.
- AeriSeal Lung sealant product for lung volume reduction, included in Pulmonx's safety and performance documentation alongside Zephyr Valve and Chartis System as part of the emphysema treatment ecosystem.
Quantifiable outcome
- 18% FEV1 improvement over control
- +3 more outcomes
Companies that use Pulmonx
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Pulmonx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Pulmonx partnerships and signals
Strategic signalScale indicators9 records
Recent moves5 records
Expansion highlights6 records
Pulmonx competitors and assessment
Company assessmentEmerging players
- Intuitive Surgical: Intuitive Surgical's Ion robotic bronchoscopy platform competes in the bronchoscopy procedure ecosystem where Zephyr Valves are implanted. As robotic bronchoscopy becomes standard for lung diagnostics and interventions, Ion could enable competing therapeutic approaches.
- Penumbra: Penumbra has expanded into pulmonary thrombectomy and lung intervention. While historically focused on vascular thrombectomy, its move into pulmonary procedures creates partial overlap with interventional pulmonology workflows where Pulmonx operates.
- Broncus Medical: Broncus Medical develops lung navigation and bronchoscopy tools (including Archimedes Virtual Bronchoscopy), competing in the diagnostic and procedural planning stages that overlap with Pulmonx's StratX and Chartis platforms.
- Johnson & Johnson (Auris Health/Monarch): Johnson & Johnson's Auris Health subsidiary markets the Monarch robotic bronchoscopy platform, directly competing in the bronchoscopic procedure space where Pulmonx's Zephyr Valves are deployed, with potential to enable alternative interventional therapies.
Broad incumbents
- Stryker: Stryker is a broad medical device incumbent with surgical and endoscopy instruments used in interventional procedures. While not a direct competitor in bronchoscopic valves, it operates in adjacent procedural medtech categories.
- Boston Scientific: Boston Scientific acquired PneumRx (lung volume reduction coils) and has historical investment in Pulmonx (Series C investor). It is a broad incumbent in interventional pulmonology and pulmonary devices with overlapping interest in lung volume reduction.
- Medtronic: Medtronic is a large medical device incumbent with respiratory and pulmonary offerings, including ventilation and interventional products. While not a direct competitor in endobronchial valves, it operates in the broader pulmonary disease management space.
- Olympus Corporation: Olympus is the parent of Spiration (direct competitor) and a global leader in bronchoscopy equipment and endoscopy. Olympus's installed base of bronchoscopes creates a channel and ecosystem overlap with Pulmonx's interventional pulmonology products.
Others
- Karl Storz: Karl Storz is a leading manufacturer of rigid and flexible endoscopes used in bronchoscopy procedures. As a supplier of the visualization platforms where Zephyr Valves are implanted, it is an ecosystem participant rather than a direct therapeutic competitor.
Direct peers
- Spiration (Olympus): Spiration, an Olympus subsidiary, markets the Spiration Valve System, an endobronchial valve for treating severe emphysema. This is the most direct competitor to Pulmonx's Zephyr Valve in bronchoscopic lung volume reduction.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Pulmonx social profiles
Digital presencePulmonx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pulmonx leadership team
Management profileNumber of profiles
Profiles5 records
Pulmonx funding detail
Funding detailFunding overview
Funding rounds11 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pulmonx M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pulmonx
What does Pulmonx do?
Pulmonx develops and commercializes minimally invasive medical devices and digital diagnostic platforms for the treatment of severe COPD/emphysema. Its core offering is the Zephyr Endobronchial Valve, a one-way nitinol and silicone valve implanted bronchoscopically to reduce hyperinflation in damaged lung regions without surgery. The offering is supported by the Chartis Pulmonary Assessment System, the StratX and LungTraX cloud-based CT analysis platforms, and AeriSeal lung sealant, sold to hospitals and specialized treatment centers worldwide.
Is Pulmonx a public or private company?
Pulmonx is a public company. It is classified as public and is currently operating.
When was Pulmonx founded?
Pulmonx was founded in 1995. It employs 251 to 500 people.
Where is Pulmonx based?
Pulmonx is headquartered in Redwood City, United States, in the North America region.
How does Pulmonx make money?
Three revenue lines are on record. Zephyr Valve Sales are the primary driver. The others are chartis System Sales and diagnostic Platform Services.
Who are Pulmonx's main competitors?
Emerging players on record are Intuitive Surgical, Penumbra, Broncus Medical and Johnson & Johnson (Auris Health/Monarch). Broad incumbents are Stryker, Boston Scientific, Medtronic and Olympus Corporation. Karl Storz is listed as an others. Spiration (Olympus) is listed as a direct peer.
Does Pulmonx have an API?
No public API is recorded for Pulmonx.
What industry is Pulmonx in?
Pulmonx's product category is Interventional Pulmonology Medical Devices. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 3391 and its SIC code is 3841.